Glaukos heads into its third-quarter report carrying a full-year forecast that management lifted to $680 million to $700 million, well above the $620 million to $635 million range it offered just a quarter earlier. That is a bold statement of confidence in its two growth engines, the iDose glaucoma implant and the Epioxa keratoconus therapy. The catch is that management paired that optimism with an unusually cautious tone about the very quarter now being reported, citing a seasonal dip in ophthalmology volumes and a reimbursement transition for Epioxa. The October 28 release, due after the close, will show which of those two messages deserves more weight.

The Street is looking for a loss of $0.12 per share on revenue of $168.8 million. That would mean revenue growth of about 26% from the year-ago $133.5 million and a narrower loss than the $0.16 posted a year ago. Yet the revenue estimate sits roughly $17 million below the $185.6 million Glaukos reported in the second quarter, implying a meaningful sequential decline. Management's own framing pointed to only minimal sequential growth for iDose rather than a pullback, so a drop of that size would have to come from softer glaucoma procedure volumes and turbulence in corneal health. Meanwhile, the full-year consensus of roughly $628 million still sits below the bottom of the new guidance, suggesting many estimates have not caught up. Taken together, the quarterly bar looks modest relative to what management has signaled for the year.

The iDose trajectory is the core of the story. Quarterly sales climbed from about $40 million to $45 million to $54 million before a substantial step-up in the second quarter, and the company introduced full-year iDose guidance of $275 million to $285 million. Second-quarter strength came from broader Medicare contractor coverage, newly contributing professional fees and rising commercial and Medicare Advantage use. Holding that elevated base through a seasonally weak summer would validate the idea that adoption is structural rather than a one-quarter surge. Early evidence that re-administration procedures are adding volume would strengthen the case further. A visible step back, by contrast, would give weight to management's reluctance to call the second quarter a trend.

Epioxa is the newer and riskier variable. It produced its first material quarter at $11 million, backed by payer coverage exceeding 100 million commercial lives and a treatment network reaching about 65% of the U.S. population. The permanent J-code that took effect July 1 should ease billing over time, but management warned it would trigger a partial reset in payer contracting and prior authorizations. Investors should look for signs that the backlog of patients awaiting approval is converting despite that friction, and for any change in realized pricing, which has run near $60,000 against a $78,500 list price because of 340B discounts.

Profitability is the other thread. Gross margin improved to roughly 85%, and management described its path to cash-flow breakeven as increasingly near-term. That claim must coexist with operating expense guidance that has climbed each quarter, now near $600 million for the year as clinical and commercial spending rises. Further margin gains from the iDose and Epioxa mix would help offset that spending; another expense increase without matching revenue upside would blur the profitability message.

The market has not given Glaukos much credit since the last report. Shares have slipped 7.4% while the S&P 500 gained 4.1%, though the stock, near $167, sits mid-range between its post-report high of $191.62 and low of $146.39 and comfortably above its 200-day average. Sentiment remains mildly bearish but slightly less so than a quarter ago. The verdict will hinge on whether iDose holds its second-quarter gains through the seasonal lull while Epioxa navigates the J-code reset intact, because that combination is what supports the raised outlook and the nearer path to profitability.